If You Invested in Naturl Alt Intl (NAII)

Natural Alternatives International, Inc. (NASDAQ: NAII) is a formulator, manufacturer, and marketer of customized nutritional supplements. According to company disclosures, NAI is headquartered in Carlsbad, California and operates in the medicinal and botanical manufacturing space within the broader manufacturing sector. The company serves customers in the United States and internationally and is engaged in both private-label contract manufacturing and patent and trademark licensing activities related to nutritional and healthcare products.

NAI’s core operations include formulating, manufacturing, and marketing nutritional supplements. Based on its public descriptions, the company offers vitamins, minerals, herbs, and other nutritional supplements, as well as other healthcare products, to customers that market and distribute these products under their own brands. The Private-Label Contract Manufacturing segment provides manufacturing services to companies that sell nutritional supplements and related healthcare products, while the Patent & Trademark Licensing segment generates royalty income from license and supply agreements associated with the sale of branded ingredients.

Business Segments and Revenue Drivers

NAI reports that it operates through two main business segments: Private-Label Contract Manufacturing and Patent & Trademark Licensing. The company states that it derives the majority of its revenue from private-label contract manufacturing, where it manufactures nutritional supplements and other healthcare products for third-party brand owners. These customers then market and distribute the finished products to consumers in various markets.

The Patent & Trademark Licensing segment is associated with NAI’s branded ingredient business, primarily centered on CarnoSyn® beta-alanine and related products. NAI receives royalty, licensing, and raw material sales revenue from license and supply agreements tied to CarnoSyn® beta-alanine and its derivatives. Company press releases also highlight the development and commercialization of TriBsyn™, described as a carnosine booster derived from CarnoSyn® beta-alanine and formulated using proprietary technology.

CarnoSyn® Brands and TriBsyn™

NAI reports that CarnoSyn® Brands feature three clinically studied, patented and patent-pending ingredients available exclusively from the company: CarnoSyn® instant release beta-alanine powder, SR CarnoSyn® sustained release beta-alanine tablets, and TriBsyn™ powder. Public disclosures state that TriBsyn™ is a patent-pending formula that utilizes proprietary technology to increase beta-alanine bioavailability and absorption while effectively eliminating the common paresthesia sensation associated with efficacious dosages of beta-alanine.

In a published clinical study summarized by NAI and CarnoSyn® Brands, TriBsyn™ is described as an encapsulated low-dose beta-alanine complex that increased plasma beta-alanine concentrations compared to conventional beta-alanine, with reported elimination of paresthesia in the study group receiving TriBsyn™. NAI indicates that TriBsyn™ is positioned as a carnosine booster with applications in dietary supplements, medical foods, and other fortified food products, with a focus on areas such as muscle vitality, cognitive performance, and healthy aging.

Strategic Partnering and Service Offering

Across multiple press releases, NAI describes itself as providing strategic partnering services to its customers. The company states that its partnership approach offers a range of nutritional products and services to clients, including:

• Scientific research and, in some disclosures, clinical studies
• Proprietary ingredients, including CarnoSyn® beta-alanine and TriBsyn™
• Customer-specific nutritional product formulation
• Product testing and evaluation
• Marketing management and support
• Packaging and delivery system design
• Regulatory review
• International product registration assistance

These services are presented by NAI as part of its integrated offering to brand-owner customers that seek support from formulation through manufacturing and regulatory processes.

Customer Relationships and Manufacturing Agreements

NAI’s disclosures highlight long-term relationships with key customers. For example, the company reports a multi-decade relationship with The Juice Plus+ Company, described as a globally recognized provider of plant-based whole-body nutritional products. In an 8-K filing and corresponding press release, NAI announced a new multi-year Manufacturing Agreement with Juice Plus+ covering capsule and powder products sold in over 24 markets. The agreement sets forth terms for NAI to manufacture and supply Juice Plus+ products within 24 countries, with an initial term ending July 16, 2027.

NAI also notes that growth in its private-label contract manufacturing sales has been driven at various times by increased orders from existing customers and shipments to new customers. Company commentary in earnings releases references efforts to expand client relationships, diversify channels, and support new product launches that incorporate NAI’s proprietary ingredients.

Financial Reporting and Exchange Listing

Natural Alternatives International, Inc. is incorporated in Delaware and, according to its SEC filings, its common stock trades on the NASDAQ under the symbol NAII. The company files periodic financial statements and current reports with the U.S. Securities and Exchange Commission, including Form 10-K annual reports, Form 10-Q quarterly reports, and Form 8-K current reports describing material events such as credit facility amendments, manufacturing agreements, and shareholder meeting results.

Recent earnings press releases describe NAI’s financial performance in terms of net sales, segment contributions from private-label contract manufacturing and CarnoSyn® beta-alanine royalty, licensing and raw material sales, and factors affecting profitability such as factory capacity utilization, sales mix, manufacturing costs, and legal and administrative expenses. The company also reports on its cash position, working capital, borrowing capacity under its credit facility, and balance sheet metrics.

Capital Structure and Credit Facility

NAI’s SEC filings indicate that the company maintains a credit facility with Wells Fargo Bank, National Association. In a June 2025 8-K filing, NAI reported entering into an amended credit facility that extended the term of its existing credit agreement to December 31, 2026 and adjusted the maximum principal amount available under the revolving line of credit. The filing notes that the company’s powder processing facility in Carlsbad, California was added as security for the amended credit agreement, and that related agreements such as the credit agreement amendments, revolving line of credit note modification, and deed of trust modification were executed.

In a December 2025 8-K filing, NAI disclosed that for its fiscal first quarter ended September 30, 2025, it was not in compliance with certain financial covenants under the credit agreement, specifically maximum net loss and fixed charge coverage ratio covenants. The company reported entering into a Waiver and Release Agreement with Wells Fargo under which the bank waived all related defaults and confirmed that the credit agreement and related agreements remained in full force and effect.

Corporate Governance and Shareholder Matters

NAI’s proxy statement and related 8-K filings describe its corporate governance and shareholder voting processes. The company holds an Annual Meeting of Stockholders, which, according to recent proxy materials, is conducted as an online meeting via live webcast. Shareholders of record as of a specified record date are entitled to vote on matters such as the election of directors, amendments to equity incentive plans, ratification of the independent registered public accounting firm, advisory votes on executive compensation, and the frequency of such advisory votes.

A December 2025 8-K filing summarizing the results of the annual meeting reports that shareholders voted on the election of a Class II director, approval of the First Amendment to the 2020 Omnibus Equity Incentive Plan, ratification of the company’s independent registered public accounting firm, advisory approval of named executive officer compensation, and the advisory frequency of future compensation votes. The filing indicates that these proposals were approved, with shareholders supporting a three-year frequency for advisory votes on executive compensation.

Research, Clinical Evidence, and Industry Positioning

NAI emphasizes scientific support for its proprietary ingredients. In collaboration with CarnoSyn® Brands, the company announced the publication of a clinical trial in the journal Food Hydrocolloids for Health evaluating TriBsyn™. The study, as described in NAI’s public communication, was a randomized, double-blind, single-dose, three-treatment, three-way crossover oral bioavailability study in healthy older adults under fasting conditions. The trial compared TriBsyn™ with low and high doses of conventional beta-alanine and reported increased plasma beta-alanine concentrations and reduced sensory side effects for TriBsyn™.

NAI and CarnoSyn® Brands also participate in scientific and industry conferences. For example, they reported exhibiting at the ESPEN Congress on Clinical Nutrition & Metabolism and the European Geriatric Medicine Society Congress to discuss clinical evidence related to TriBsyn™ and to engage with professionals in clinical nutrition and geriatric medicine.

Stock Classification and Investor Considerations

Natural Alternatives International, Inc. is a publicly traded company in the manufacturing sector, focused on nutritional supplements and related patented ingredients. It is not described in the provided materials as part of a major large-cap index such as the S&P 500. Investors researching NAII stock can review the company’s SEC filings, earnings press releases, and other public disclosures to understand its segment performance, customer relationships, proprietary ingredient portfolio, and capital structure.

FAQs about Natural Alternatives International, Inc. (NAII)

• What does Natural Alternatives International, Inc. do?
  According to its public descriptions, NAI formulates, manufactures, and markets nutritional supplements and other healthcare products. It provides private-label contract manufacturing services to companies that market and distribute these products and also generates revenue from patent and trademark licensing related to proprietary ingredients such as CarnoSyn® beta-alanine.
• What are NAI’s main business segments?
  NAI reports two primary segments: Private-Label Contract Manufacturing, which involves manufacturing nutritional supplements and healthcare products for third-party brand owners, and Patent & Trademark Licensing, which includes royalty income and related revenue from license and supply agreements associated with CarnoSyn® beta-alanine and similar branded ingredients.
• Where is NAI headquartered?
  Company press releases and SEC filings state that Natural Alternatives International, Inc. is headquartered in Carlsbad, California.
• What is CarnoSyn®?
  CarnoSyn® is described by NAI as a clinically studied, patented beta-alanine ingredient available exclusively from the company. CarnoSyn® Brands include instant release beta-alanine powder, SR CarnoSyn® sustained release beta-alanine tablets, and TriBsyn™ powder, which are used in nutritional supplement and wellness applications.
• What is TriBsyn™ and how is it related to NAI?
  TriBsyn™ is described as a patent-pending carnosine booster derived from CarnoSyn® beta-alanine and formulated using proprietary technology to increase beta-alanine bioavailability and absorption while eliminating the common paresthesia sensation. It is part of the CarnoSyn® Brands portfolio, which NAI states is available exclusively from the company.
• How does NAI work with brand-owner customers?
  NAI describes a strategic partnering approach in which it offers scientific research, proprietary ingredients, customer-specific product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review, and international product registration assistance to its clients.
• What exchange does NAII trade on?
  SEC filings identify NAII as the trading symbol for Natural Alternatives International, Inc. common stock on the NASDAQ exchange.
• Does NAI operate internationally?
  NAI states that it offers nutritional supplements and other healthcare products to customers within the United States and internationally. It also reports a manufacturing agreement with The Juice Plus+ Company to supply products within 24 countries.
• What type of regulatory filings does NAI submit?
  As a U.S. public company, NAI files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K with the SEC. These filings cover financial results, material agreements such as credit facilities and manufacturing contracts, and shareholder meeting outcomes.
• How is NAI’s credit facility structured?
  In a June 2025 8-K, NAI reported an amended credit facility with Wells Fargo that extended the term to December 31, 2026, adjusted the maximum principal amount under the revolving line of credit, and added the company’s powder processing facility in Carlsbad, California as security. A subsequent December 2025 8-K reported that Wells Fargo waived certain covenant defaults for the first quarter of fiscal 2026 and confirmed that the credit agreement remained in effect.